Condition: Coronary Artery Disease · Ischemic Heart Disease · Sponsor: Fundación EPIC
Patients receiving chronic oral anticoagulation with indication for percutaneous coronary revascularization with stent implantation, and needing for antiplatelet therapy, are at high risk of bleeding. The new generation of ultrathin strut sirolimus-eluting stent with bioabsorbable polymer allow for shorter antiplatelets regimens and could be a good option for this high-bleeding risk patients.
This description comes directly from the study's public registry record.
Juan Gabriel Córdoba Soriano, MD, PhD · 0034 967597532 · jgcordoba@foroepic.org
FUNDACION EPIC · 0034987876135 · iepic@fundacionepic.org
Always discuss trial participation with your own doctor first.
| Hospital General Universitario de Albacete | Albacete, Spain | Recruiting |
| Hospital Universitario San Juan de Alicante | Alicante, Spain | Recruiting |
| Hospital General Universitario de Merida | Badajoz, Spain | Recruiting |
| Hospital General Universitari de Castelló | Castelló, Spain | Recruiting |
| H.G.U. de Ciudad Real. | Ciudad Real, Spain | Recruiting |
| Hospital General Universitari d'Elx | Elche, Spain | Recruiting |
| Hospital Universitario de Canarias | Laguna, Spain | Recruiting |
| Hospital Doctor Jose Molina Orosa | Las Palmas de Gran Canaria, Spain | Recruiting |
| Hospital Universitario Puerta de Hierro | Majadahonda, Spain | Recruiting |
| Hospital Universitario de Navarra | Pamplona, Spain | Recruiting |
| Hospital General de Fuerteventura | Puerto del Rosario, Spain | Recruiting |
| Hospital Clinico Universitario Lozano Blesa | Zaragoza, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06863155